Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSernova Corp

Sernova Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.11 CAD -0.01 ( 4.35%)
Last update at 2026-11-04T19:24:00Z
VOLUME
97115
Market Cap
62.59M

Momentum Score

…

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.11
High
52 Week Price Range
0.12
Low
0.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sernova Corporation is a clinical-stage medical technology company developing an implantable Cell Pouch to host therapeutic cells for long-term hormone delivery, targeting insulin-dependent diabetes and other endocrine conditions. Long-term growth may be supported by successful clinical trial outcomes, regulatory approvals and partnerships or licensing that expand use of its platform. Investors may find the company attractive because the approach appears positioned to address a persistent unmet need for durable, cell-based hormone replacement.

Material risks include high clinical and regulatory uncertainty for novel cell therapies, manufacturing and scale-up challenges, limited revenue history and frequent need for external capital that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.69
ROE
-726.29%
Net Debt
17.02M
ROCE
62.75%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -15.84M -32.19M -39.63M -24.42M -6.97M
Net income -15.74M -32.19M -39.00M -24.54M -7.01M
Selling general administrative 7.50M 8.97M 8.46M 7.83M 2.29M
Selling and marketing expenses - - 8.42M - -
Gross profit -0.34M - -0.45M - -
Reconciled depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Ebit -15.08M -31.66M -40.50M -24.18M -6.87M
Ebitda -14.74M -31.25M -40.19M -23.74M -6.60M
Depreciation and amortization 0.34M 0.41M 0.31M 0.44M 0.27M
Operating income -15.12M -31.84M -41.13M -24.18M -6.87M
Other operating expenses 15.12M 31.84M 41.13M 24.75M 6.94M
Interest expense 0.75M 0.59M 0.03M 0.12M 0.06M
Tax provision 0.01M 0.01M 0.00M - -
Interest income 0.03M 0.54M 1.50M 0.33M 0.02M
Net interest income -0.73M -0.20M 1.47M 0.46M 0.01M
Income tax expense -0.09M 0.01M -0.63M 0.12M 0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 14.78M 31.84M 41.13M 24.75M 6.94M
Cost of revenue 0.34M - 0.45M - -
Total other income expense net -0.71M -0.35M 1.50M -0.24M -0.10M
Net income from continuing ops -15.74M -32.19M -39.00M -24.42M -6.97M
Net income applicable to common shares -15.74M -32.19M -39.00M -24.42M -6.97M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.76M 7.53M 22.11M 52.48M 29.82M
Intangible assets - - 0.00M 0.52M 0.72M
Other current assets 0.14M 0.16M 0.16M 0.17M -
Total liab 25.84M 20.48M 9.59M 4.88M 1.75M
Total stockholder equity -25.08M -12.96M 12.51M 47.61M 28.07M
Other current liab 8.56M - 2.61M 0.99M 0.98M
Common stock 118.70M - 110.99M 110.99M 74.01M
Capital stock 118.70M 116.68M 110.99M 110.99M 74.01M
Retained earnings -166.10M -150.36M -118.17M -79.17M -54.75M
Good will - - 0.32M - -
Other assets 0.22M - 0.00M 0.22M 0.21M
Cash 0.27M 6.01M 8.72M 3.78M 27.87M
Total current liabilities 24.80M 20.02M 9.59M 4.74M 1.48M
Net debt 17.02M - -8.59M -3.50M -27.48M
Short term debt 16.24M - 0.14M 0.14M 0.12M
Short long term debt total 17.28M - 0.14M 0.28M 0.39M
Other stockholder equity 21.79M - 19.69M 15.79M 8.81M
Property plant equipment 0.02M - - 0.65M 0.56M
Total current assets 0.52M 6.47M 21.02M 51.09M 28.33M
Net tangible assets - - - 47.09M 27.35M
Short term investments - 0.00M 11.08M 46.00M -
Net receivables 0.12M - 1.05M 1.15M 0.45M
Long term debt 1.04M - - - 0.00M
Accounts payable 5.16M 17.24M 6.85M 3.61M 0.38M
Accumulated other comprehensive income 0.54M - - - -
Non currrent assets other 0.22M - 0.26M 0.22M 0.60M
Non current assets total 0.24M 1.06M 1.08M 1.39M 1.49M
Capital lease obligations 0.00M 0.57M 0.14M 0.28M 0.39M
Long term debt total 1.04M - - 0.14M 0.28M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments 0.00M 11.12M 34.78M -46.34M -0.23M
Change to liabilities - - - 3.31M 0.46M
Total cashflows from investing activities 0.02M 11.12M 34.78M -46.34M -0.23M
Net borrowings 4.82M -0.17M -0.17M -0.17M -0.03M
Total cash from financing activities 5.14M 5.07M 0.50M 36.66M 31.00M
Change to operating activities - - - -0.16M 0.14M
Net income -15.74M -32.19M -39.00M -24.42M -6.97M
Change in cash -5.75M -2.71M 4.95M -24.10M 23.92M
Begin period cash flow 6.01M 8.72M 3.78M 27.87M 3.95M
End period cash flow 0.27M 6.01M 8.72M 3.78M 27.87M
Total cash from operating activities -10.91M -18.90M -30.34M -14.42M -6.84M
Issuance of capital stock 0.25M 4.96M 0.00M 20.28M 21.13M
Depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Other cashflows from investing activities 0.02M 0.04M -0.04M -46.01M -0.21M
Change to account receivables 0.18M 0.56M 0.23M -0.20M -0.09M
Sale purchase of stock 0.25M 4.98M 0.00M 36.51M 29.90M
Other cashflows from financing activities -0.05M 0.28M 0.68M 16.55M 9.90M
Change to netincome - - - 6.61M -0.66M
Capital expenditures 0.00M 0.00M 0.10M 0.33M 0.02M
Change in working capital 1.74M 11.16M 4.99M 2.95M 0.52M
Stock based compensation 2.30M 1.75M 3.90M 7.45M 0.22M
Other non cash items 0.52M -0.15M -0.68M -0.84M -0.88M
Free cash flow -10.91M -18.90M -30.44M -14.75M -6.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SVA
Sernova Corp		 -0.01
4.35%		 0.11 - - 65.86 24.15 36.69 -11.27
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Sernova Corp

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

RPO Central Parkway, Mississauga, ON, Canada, L5A 4H2

917-751-5713

https://www.sernova.com

8

Name Title Year Born
Mr. Frank A. Holler MBA Exec. Chairman 1957
Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. Pres, CEO & Director NA
Mr. David Swetlow C.A, C.A., CPA Chief Financial Officer NA
Mr. Douglas Maret Chief Science Officer NA
Mr. Christopher Barnes VP of Investor Relations NA
Mr. James T. Parsons CPA-CA, MAcc CFO & Director 1965
Dr. Modestus Obochi M.B.A., Ph.D. Chief Business Officer NA
Dr. Frank Shannon M.D. Vice President of Clinical Development & Regulatory Affairs NA
Mr. Jonathan M. N. Rigby M.B.A., MBA Executive Chairman 1968
Mr. David Burke Vice President of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…